Steve Thorne | Chief Scientific Officer
Kalivir Immunotherapeutics

Steve Thorne, Chief Scientific Officer, Kalivir Immunotherapeutics

Stephen Thorne co-founded Kalivir in 2019 and currently serves as Chief Scientific Officer. He is a leader in the field of oncolytic viral immunotherapy and previously co-founded Western Oncolytics, BioEclipse and Jennerex, which is currently advancing Pexa-Vec through late-stage clinical trials. Stephen was a Professor of Cell Biology and Immunology at the University of Pittsburgh and received his B.A. from Oxford University, UK and Ph.D. from Imperial College of London. Stephen has served in post doctorate roles at Surrey University, Cancer Research UK, and Stanford University and has authored more than 100 scientific publications in the field.


Day 1 - November 28 @ 16:50

Novel Vaccinia Enhanced Template (VET) oncolytic platform

last published: 02/Jan/24 12:15 GMT

back to speakers